Trial NCT03787251

View at ClinicalTrials.gov 
Org. Study IDs: Nanjing Drum Tower Hospital

Last trial update was posted on 2022-04-19

MeSH Interventions

Apatinib

MeSH Conditions

Esophageal Neoplasms Recurrence

Other Conditions


Stopping Reasons

In China, apatinib has been approved as an indication drug for esophageal squamous cell carcinoma, which makes it very difficult for our clinical trial to enroll patients. We regret that we failed to implement the design as planned.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID